XPEV XPEV
Company Profile ↓Company Overview
XPEV (XPEV) is a publicly traded company listed on with a market capitalization of $24.85B. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Net profit has compounded at 29.2% per year over the last five years.
Revenue has grown at a 41.9% CAGR over the past five years.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $76.72B (+87.7% YoY); net profit $-1.14B.
- Trailing 12 Months Year-on-year growth — revenue +87.7%.
- 5-Year Trend Long-term compounding — revenue CAGR 41.9%, profit CAGR 29.2%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 41.89% |
| 1 Year: | 87.73% |
Compounded Profit Growth
| 5 Years: | 29.18% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -27.98% |
| 6 Months: | -30.07% |
| 3 Months: | -20.25% |
| 1 Month: | -4.41% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)45.75 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 41.9% over 5 years.
- Profit CAGR of 29.2% over 5 years.
- Generates positive free cash flow.
CONS
- Trading 53.7% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 15.81B | 18.27B | 20.38B | 22.25B | 13.03B |
| Cost of Revenue | 13.35B | 15.11B | 16.28B | 17.51B | 10.35B |
| Gross Profit | 2.46B | 3.17B | 4.10B | 4.74B | 2.68B |
| Operating Expenses | 3.38B | 4.14B | 4.78B | 4.83B | 4.61B |
| Operating Income | -923.22M | -968.65M | -677.22M | -85.00M | -1.93B |
| EBITDA | -519.84M | -455.89M | -294.35M | 493.20M | -1.60B |
| Interest Expense | 128.94M | 75.16M | 99.35M | 76.48M | 164.99M |
| Pretax Income | -648.78M | -531.05M | -393.70M | 416.72M | -1.76B |
| Tax Provision | 7.99M | -9.42M | -7.11M | 22.13M | 9.25M |
| Net Income | -664.05M | -477.75M | -380.87M | 383.21M | -1.78B |
| Diluted EPS | -0.70 | -0.50 | -0.40 | 0.40 | -1.86 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 26.86B | 30.68B | 40.87B | 76.72B |
| Cost of Revenue | - | 23.77B | 30.22B | 35.02B | 62.25B |
| Gross Profit | - | 3.09B | 451.15M | 5.85B | 14.47B |
| Operating Expenses | - | 11.79B | 11.37B | 12.74B | 17.13B |
| Operating Income | - | -8.71B | -10.92B | -6.89B | -2.65B |
| EBITDA | - | -7.58B | -8.02B | -2.91B | 2.21B |
| Interest Expense | - | 132.19M | 268.67M | 343.98M | 379.93M |
| Pretax Income | - | -9.12B | -10.39B | -5.83B | -1.16B |
| Tax Provision | - | 24.73M | 36.81M | -69.78M | 13.59M |
| Net Income | - | -9.14B | -10.38B | -5.79B | -1.14B |
| Diluted EPS | - | -10.68 | -11.92 | -6.12 | -1.20 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 71.49B | 84.16B | 82.71B | 103.16B |
| Current Assets | - | 43.53B | 54.52B | 49.74B | 63.25B |
| Cash & Equivalents | - | 14.61B | 21.13B | 18.59B | 17.33B |
| Inventory | - | 4.52B | 5.53B | 5.56B | 10.38B |
| Receivables | - | 3.87B | 2.72B | 2.45B | 2.00B |
| Total Liabilities | - | 34.58B | 47.83B | 51.43B | 72.79B |
| Current Liabilities | - | 24.11B | 36.11B | 39.86B | 58.11B |
| Long Term Debt | - | 6.38B | 6.93B | 6.98B | 6.76B |
| Total Debt | - | 12.83B | 15.39B | 15.94B | 19.55B |
| Total Equity | - | 36.91B | 36.33B | 31.27B | 30.37B |
| Shares Outstanding | - | 1.73B | 1.89B | 1.90B | 1.91B |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -8.23B | 956.16M | -2.01B | 8.26B |
| Investing Cash Flow | - | 4.85B | 631.17M | -1.26B | -7.33B |
| Financing Cash Flow | - | 6.00B | 8.02B | 669.32M | 514.76M |
| Capital Expenditure | - | -4.68B | -2.31B | -2.43B | -3.35B |
| Free Cash Flow | - | -12.91B | -1.36B | -4.44B | 4.91B |
| Net Change in Cash | - | 2.62B | 9.60B | -2.60B | 1.44B |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 11.5% | 1.5% | 14.3% | 18.9% |
| Operating Margin % | - | -32.4% | -35.6% | -16.9% | -3.5% |
| Net Margin % | - | -34.0% | -33.8% | -14.2% | -1.5% |
| ROE % | - | -24.8% | -28.6% | -18.5% | -3.8% |
| ROCE % | - | -18.4% | -22.7% | -16.1% | -5.9% |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for XPEV
XPEV — Frequently Asked Questions
What is the current share price of XPEV?
As of 2026-08-02 19:16 PDT, XPEV trades at $13.00 on NASDAQ/NYSE. Its 52-week range is $12.09 to $28.07.
What is the market capitalisation of XPEV?
XPEV has a market capitalisation of $24.85B on NASDAQ/NYSE.
What is the P/E ratio of XPEV?
XPEV trades at a trailing price-to-earnings (P/E) ratio of -10.83. Its price-to-book (P/B) ratio is 0.82.
What is the return on equity (ROE) of XPEV?
XPEV has a return on equity (ROE) of -3.75%. Its return on capital employed (ROCE) is -1.72%.
Is XPEV a good stock to buy?
This page provides a data-driven analysis of XPEV, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.